Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [820]

Challenges to developing the quality of complex cancer surgery in LMICs

Dr Shailesh V. Shrikhande - Tata Memorial Hospital, Mumbai, India

Challenges to developing the quality of complex cancer surgery in LMICs ( Dr Shailesh V. Shrikhande - Tata Memorial Hospital, Mumbai, India )

ESMO 2022: Breast and ovarian trial analysis

Dr Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2022: Breast and ovarian trial analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

Neoadjuvant immunotherapy improves outlook in high-risk melanoma

Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA

Neoadjuvant immunotherapy improves outlook in high-risk melanoma ( Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA )

ESMO 2022: Highlights, commentary and analysis

Dr Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2022: Highlights, commentary and analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

ESMO 2022: Breast cancer highlights

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

ESMO 2022: Breast cancer highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

Sotorasib demonstrates superior PFS vs docetaxel for previously treated non...

Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA

Sotorasib demonstrates superior PFS vs docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation ( Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA )

Cabozantinib in combination w/ nivolumab and ipilimumab of IMDC intermediate or...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

Cabozantinib in combination w/ nivolumab and ipilimumab of IMDC intermediate or poor risk significantly improved PFS vs PBO ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

Abemaciclib plus NSAI for HR+, HER2- advanced breast cancer - MONARCH 3 interim...

Prof Matthew P Goetz - Mayo Clinic, Rochester, USA

Abemaciclib plus NSAI for HR+, HER2- advanced breast cancer - MONARCH 3 interim data ( Prof Matthew P Goetz - Mayo Clinic, Rochester, USA )

Lasofoxifene vs fulvestrant for locally advanced/metastatic ER+/HER2- breast...

Prof Matthew P Goetz - Mayo Clinic, Rochester, USA

Lasofoxifene vs fulvestrant for locally advanced/metastatic ER+/HER2- breast cancer: ELAINE trial ( Prof Matthew P Goetz - Mayo Clinic, Rochester, USA )

Nivolumab and ipilimumab with tumour-infiltrating lymphocytes to treat triple...

Dr Iris Nederlof - The Netherlands Cancer Institute, Amsterdam, Netherlands

Nivolumab and ipilimumab with tumour-infiltrating lymphocytes to treat triple-negative breast cancer ( Dr Iris Nederlof - The Netherlands Cancer Institute, Amsterdam, Netherlands )

Atezolizumab improves on single-agent chemo for NSCLC not eligible for platinum...

Prof Siow-Ming Lee - University College London, London, UK

Atezolizumab improves on single-agent chemo for NSCLC not eligible for platinum-containing regimen ( Prof Siow-Ming Lee - University College London, London, UK )

Results from a phase 3 study of 1L atezolizumab vs single-agent chemotherapy in...

Prof Siow-Ming Lee - University College London, London, UK

Results from a phase 3 study of 1L atezolizumab vs single-agent chemotherapy in pts with NSCLC ( Prof Siow-Ming Lee - University College London, London, UK )

More from ecancer